Brief: Jaguar Health Enters Exclusive Crofelemer License, Commercialization Agreement With Synworld Technologies For Canalevia
29/06/2022 13:36
June 29 (Reuters) - Jaguar Health Inc JAGX.O :
* JAGUAR HEALTH ENTERS EXCLUSIVE CROFELEMER LICENSE AND
COMMERCIALIZATION AGREEMENT WITH SYNWORLD TECHNOLOGIES FOR
CANALEVIA FOR TREATMENT OF DIARRHEA IN DOGS IN CHINA
* JAGUAR HEALTH INC - LICENSE FEES OF $5.0 MILLION, AND UP
TO $5.0
MILLION IN UNREGISTERED EQUITY INFUSION, OVER NEXT 24 MONTHS
* JAGUAR HEALTH - SERVICE AGREEMENT OF UP TO $5.0 MILLION
PAYABLE
IN UNREGISTERED JAGUAR STOCK TO SYNWORLD TO SUPPORT APPROVAL OF
CROFELEMER IN CHINA
Source text for Eikon: ID:
Further company coverage: JAGX.O